Webinar | March 9, 2017

Biologics Manufacturing - Is Your Company Ready?

Source: Dassault Systèmes BIOVIA

Biologics sales are growing faster than small molecule. In fact, it’s predicted that protein-based science will account for more than 25% of the product portfolio in the very near future due to superior therapeutic efficacy, premium pricing, 12 year exclusivity (i.e., US), “biosimilar” replication difficulty, and satisfying the shift towards personalized medicine. However, current best practices in pharmaceutical manufacturing are not transferable and require innovative approaches to deliver effectively.  This webcast will not only reveal the current trends and challenges in Biologics manufacturing, but also new business models and how technology can drive high quality and operational efficiency.